Dr Cindy Chu
Cindy’s main research area is in Plasmodium vivax malaria. She has conducted studies on the epidemiology of P. vivax recurrence as well as efficacy trials with the schizonticidal agents chloroquine and dihydroartemisinin-piperaquine. Her current focus is on the radical curative treatment of P. vivax using 8-aminoquinolines and the haemolytic effects of this class of drugs in G6PD heterozygous females. The goal of this research is for the safe delivery of primaquine and tafenoquine for treatment of P. vivax malaria and within the context of P. vivax elimination.
SMRU free healthcare
Chloroquine and primaquine induced haematocrit changes to G6PD heterozygote
Plasmodium vivax recurrences
An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples
Adam I. et al, (2022), Wellcome Open Research, 7, 136 - 136
An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples.
MalariaGEN None. et al, (2022), Wellcome open research, 7
The prevention and treatment of Plasmodium vivax malaria.
Chu CS. and White NJ., (2021), PLoS medicine, 18
Tafenoquine: a toxicity overview.
Chu CS. and Hwang J., (2020), Expert Opin Drug Saf
Vivax malaria in pregnancy and lactation: a long way to health equity
Brummaier T. et al, (2020), Malaria Journal, 19